Novel HIF-2α Inhibitor Casdatifan Shows Promise in Advanced Kidney Cancer Phase 1 Trial
Key Insights
Dana-Farber researchers report casdatifan, a novel HIF-2α (search) inhibitor, demonstrates promising clinical activity and tolerability in heavily pretreated clear cell renal cell carcinoma (search) patients.
Blood-based KIM-1 (search) biomarker identified as potential early indicator of immunotherapy response in advanced kidney cancer, offering new monitoring possibilities.
Final follow-up data from CheckMate9ER (search) trial confirms long-term benefits of nivolumab-cabozantinib combination therapy in advanced renal cell carcinoma patients.
Dana-Farber Cancer Institute researchers unveiled significant advances in kidney cancer treatment at the 2025 ASCO Genitourinary Cancers Symposium in San Francisco, presenting findings across multiple studies that could reshape treatment approaches for renal cell carcinoma.
Promising Results for Novel HIF-2α Inhibitor
In a groundbreaking phase 1 trial (ARC-20 (search)), researchers led by Dr. Toni K. Choueiri evaluated casdatifan, a novel oral HIF-2α (search) inhibitor, in patients with clear cell renal cell carcinoma (search) (ccRCC) who had previously received anti-PD-(L)1 checkpoint inhibitors and anti-angiogenic therapies. The drug works by blocking HIF-2α, a key driver of cancer growth in ccRCC, by inhibiting the transcription of dependent genes. Early results indicate the treatment was well-tolerated while showing promising clinical activity in this heavily pretreated patient population.
Breakthrough in Biomarker Development
A significant advancement in patient monitoring emerged from a post-hoc analysis of the CheckMate 214 (search) trial, revealing KIM-1 (search) as a potential blood-based biomarker for tracking immunotherapy response. The study found that baseline KIM-1 levels correlate with clinical outcomes, with higher levels indicating poorer prognosis. Importantly, researchers observed that reductions in KIM-1 levels three weeks after initial combination therapy were associated with long-term treatment benefits, suggesting its utility as a minimally invasive monitoring tool.
Long-term Efficacy Confirmed for Combination Therapy
The final follow-up data from the pivotal CheckMate9ER (search) trial has reinforced the effectiveness of combining nivolumab with cabozantinib as first-line treatment for advanced renal cell carcinoma. After more than 5.5 years of median follow-up, the combination therapy continued to demonstrate superior outcomes compared to sunitinib monotherapy, including improved progression-free survival and reduced mortality risk. Patients receiving the combination therapy experienced higher response rates and better quality of life, with no new safety concerns identified during the extended follow-up period.
The findings presented at the symposium represent significant progress in the field of kidney cancer treatment, offering new therapeutic options and monitoring strategies for patients with advanced disease. These developments underscore the importance of continued research in developing targeted therapies and identifying reliable biomarkers for personalized treatment approaches.